ライフサイエンスコーパス: adenovirus vector

1 gulation of cytomegalovirus promoters in the adenovirus vector.

2 L cells or CLL cells infected with a control adenovirus vector.

3 The cDNA template was delivered by adenovirus vector.

4 imaged following dual gene transfer with an adenovirus vector.

5 c artery infusion of a replication-defective adenovirus vector.

6 eral blood stem cells using a c-kit-targeted adenovirus vector.

7 affecting lytic infection induced by a BZLF1 adenovirus vector.

8 uman primary fibroblasts using a recombinant adenovirus vector.

9 e transfected in vitro with GMF utilizing an adenovirus vector.

10 fidelity of the DNA polymerase into a human adenovirus vector.

11 n a beta-galactosidase (betagal)-recombinant adenovirus vector.

12 and mutant ATP7B in COS1 cells infected with adenovirus vector.

13 mutants of Src and Pyk2 in osteoclasts using adenovirus vectors.

14 xpressed in MC-/- or MC+/+ using recombinant adenovirus vectors.

15 was expressed by using replication-defective adenovirus vectors.

16 n recombination between two first-generation adenovirus vectors.

17 ntional strategies for fiber manipulation of adenovirus vectors.

18 the antitumor effect of the BZLF1 and BRLF1 adenovirus vectors.

19 ovirus genome should lead to optimization of adenovirus vectors.

20 plicable for other conditionally replicating adenovirus vectors.

21 py trials for cystic fibrosis have been with adenovirus vectors.

22 iruses (HSV), replication-defective HSV, and adenovirus vectors.

23 nation of gC2/gD2-CpG/alum and the UL19/UL47 adenovirus vectors.

24 ssion and for the development of recombinant adenovirus vectors.

25 rsistence of gene expression from integrated adenovirus vectors.

26 es were expressed from replication-defective adenovirus vectors.

27 B in adult rabbit ventricular myocytes using adenovirus vectors.

28 which exceed levels found after injection of adenovirus vectors.

29 and gH/gL were expressed from nonreplicating adenovirus vectors.

30 lasmid or E1-deleted (replication-defective) adenovirus vectors.

31 ntrast strikingly with findings reported for adenovirus vectors.

32 Altering adenovirus vector (Ad vector) targeting is an important

33 re that ectopic expression of BRCA1 using an adenovirus vector (Ad-BRCA1) leads to dephosphorylation

34 An adenovirus vector (Ad-CD4) was used to express CD4 in CD

35 tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar

36 apeutic replacement of the p53 gene using an adenovirus vector (Ad-p53) may be an effective alternati

37 on protocol using a wild-type p53-expressing adenovirus vector (Ad-p53) was used to identify the bind

38 th a low dose of a recombinant wild-type p53 adenovirus vector (Ad-p53), a synergistic growth inhibit

39 clinical trial of p53 gene therapy using an adenovirus vector (Ad-p53, INGN 201).

40 for the late gene U(L)20 was packaged in an adenovirus vector (Ad-U(L)20 Rz) and evaluated for its c

41 ficiency expression of REST-VP16 mediated by adenovirus vectors (Ad.REST-VP16) in medulloblastoma cel

42 Furthermore, injection of an adenovirus vector, Ad-1D8, which encodes anti-CD137 scFv

43 elivered to cells by a replication-defective adenovirus vector, Ad.CMV-GFP, and the intensity of GFP

44 randomly assigned to receive combinations of adenovirus vectors (Ad5 or Ad35) and HIV-1 envelope (Env

45 latory factors (IRF) 7 and 3 delivered by an adenovirus vector [Ad5-poIRF7/3(5D)], is a new effective

46 We constructed a chimeric adenovirus vector, Ad5/H3, by replacing the Ad5 hexon ge

47 on p53 function by using a BZLF1-expressing adenovirus vector (AdBZLF1).

48 A replication-deficient adenovirus vector (AdCMVIFN-beta) was used for the in vi

49 Mice treated with control adenovirus vector (Addl70) were not affected.

50 modified first-generation (E1A/E1B-deleted) adenovirus vector (AdE1-) in mouse tumor models.

51 pha/beta) with a replication-defective human adenovirus vector (adenovirus 5 [Ad5]) can sterilely pro

52 ere mock infected or infected with a control adenovirus vector (AdLacZ) or a vector expressing the EB

53 cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled de

54 esults of ICP0 expressed from an E1(-) E4(-) adenovirus vector (AdS.11E4ICP0) in which ICP0 expressio

55 ular endothelial growth factor (VEGF), using adenovirus vector (ADV)-mediated gene transfer, accelera

56 When administered systemically in mice, adenovirus vectors (Adv) localize primarily to hepatic t

57 Lumenal delivery of adenovirus vectors (AdV) results in inefficient gene tra

58 Infection with adenovirus vectors (AdV) results in rapid activation of

59 ine regimen using two serologically distinct adenovirus vectors afforded substantially improved prote

60 on of soluble CD8 by a replication-defective adenovirus vector allowed persistent virus expression fo

61 shRNA targeting VEGF from adenovirus vectors allows potent attenuation of VEGF and

62 nase-inactive form of BMPR-IB mediated by an adenovirus vector also inhibits eyelid opening.

63 y for humans that are centered on use of the adenovirus vector and in which existing adenovirus immun

64 denovirus vector may increase the utility of adenovirus vectors and also provides a means to efficien

65 Using replication-defective adenovirus vectors and replication-competent wild-type a

66 s that support DNA replication of E1-deleted adenovirus vectors and which can be killed by an oncolyt

67 the oncolytic efficacy of a serotype 5-based adenovirus vector; and (iii) the demonstration that epit

68 The ChAd63 chimpanzee adenovirus vector appears safe and highly immunogenic, p

69 ve demonstrated that replication-incompetent adenovirus vectors are an effective means for eliciting

70 ation that gene transfer is inefficient when adenovirus vectors are applied to the apical surface.

71 Adenovirus vectors are increasingly being used for genet

72 +) T cells elicited by replication-defective adenovirus vectors are linked to persistence of low leve

73 Adenovirus vectors are promising for use in vaccinating

74 Adenovirus vectors are widely used as vaccine candidates

75 FBP RNA, expressed via replication-defective adenovirus vectors, arrested cellular proliferation and

76 ession of FAK in Du3 (FAK(-/-)) cells via an adenovirus vector augmented the internalization of viral

77 vator cassette) in a single helper-dependent adenovirus vector backbone.

78 Adenovirus vectors based on human serotype 5 (Ad5) have

79 d oncolytic adenovirus and other E3B-deleted adenovirus vector-based therapy.

80 Adenovirus/poxvirus and adenovirus/adenovirus vector-based vaccines expressing HIV-1 mosaic

81 Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which e

82 Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543)

83 ombined immunization with adjuvanted DNA and adenovirus vector boosting.

84 ection of C18 tumors with the BZLF1 or BRLF1 adenovirus vector, but not the control vector, also sign

85 exogenous basolateral markers transduced via adenovirus vectors, but exhibited normal polarity of api

86 alent dengue virus vaccines, using a complex adenovirus vector, by incorporating the genes expressing

87 t conditionally replicating, tumor-selective adenovirus vectors can be created by modifying the effic

88 Surface modification of adenovirus vectors can improve tissue-selective targetin

89 a show that ex vivo infection by recombinant adenovirus vectors can result in vascular expression of

90 mediated gene transfer but also by using an adenovirus vector carrying both the transgene cassette t

91 Adenovirus vector carrying MMP2 sequence and specific sm

92 this goal, we constructed a helper-dependent adenovirus vector carrying the beta-globin locus control

93 Cultured myocytes were infected with adenovirus vector carrying the cDNA of wild-type SERCA1,

94 labeled with a nuclear dye or a recombinant adenovirus vector carrying the lacZ gene survive graftin

95 Using RNA interference technology and adenovirus vectors carrying small-interfering RNA constr

96 introduced into primary hepatocytes with an adenovirus vector caused a total loss of PEPCK-C mRNA an

97 These data indicate that very low doses of Adenovirus-vectored consensus vaccines induce superior l

98 P1 expressed in marrow stromal cells with an adenovirus vector containing 29.7 phosphates/mol was an

99 le rats were injected preventatively with an adenovirus vector containing human IL-13 (AxCAIL-13), a

100 nce after intravitreous administration of an adenovirus vector containing the firefly luciferase gene

101 administered 5 x 10(8) PFU of a recombinant adenovirus vector containing the murine IFN-gamma cDNA (

102 Second, we have generated adenovirus vectors containing antisense Ku70 under the c

103 CYP2E1 promoter constructs were used to make adenovirus vectors containing CYP2E1 promoter-driven luc

104 In addition, when cells were infected with adenovirus vectors containing the heat-inducible interle

105 -delta isoforms but not PKC-zeta isoform by adenovirus vectors containing the respective cDNA enhanc

106 Adenovirus vectors containing UL19 and UL47 stimulated h

107 Recombinant adenovirus vectors containing vIL-10 (Ad-vIL-10) or beta

108 the STEP study has led to the development of adenovirus vectors derived from alternative serotypes, s

109 A major obstacle to the use of adenovirus vectors derived from common human serotypes,

110 ng adenovirus-specific T cells can extend to adenovirus vectors derived from rare serotypes.

111 expression/function could be created during adenovirus vector design that would increase the therape

112 Vaccines based on replication-deficient adenovirus vectors either alone or in combination with a

113 Different adenovirus vectors either expressing TRAM alone or co-ex

114 This adenovirus vector enabled efficient delivery of the L1 e

115 We previously documented that the adenovirus vector encoding 11 tandem repeats of Abeta1-6

116 cAMP and abolished in cells infected with an adenovirus vector encoding an inhibitor protein of cAMP-

117 alpha/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1al

118 A recombinant adenovirus vector encoding the ILK gene was constructed

119 tani infection in mice can be elicited by an adenovirus vector encoding the tetanus toxin C fragment

120 tion of targets with a replication-deficient adenovirus vector encoding UL18 (RAd-UL18).

121 ZAP-70-negative CLL B cells infected with an adenovirus vector encoding ZAP-70 induced significantly

122 ibition of these transcription factors using adenovirus vectors encoding either the IkappaBalpha repr

123 that local delivery of replication-defective adenovirus vectors encoding IL-23 (AdIL-23) greatly stim

124 ed from murine joints following injection of adenovirus vectors encoding murine OSM and/or murine TNF

125 Similar adenovirus vectors encoding wild-type ICP4, wild-type an

126 tic cells expressing mEGP from a recombinant adenovirus vector exhibited a muted anti-adenovirus immu

127 In control infections, an adenovirus vector expressed green fluorescent protein ef

128 neic C57BL/6 mice, intratumoral injection of adenovirus vector expressing 15-PGDH (pAd-15-PGDH) signi

129 of normal MEFs, Hep2, or A549 cells with an adenovirus vector expressing a dominant-negative (DN) Ik

130 pool of NF-kappaB in human macrophages by an adenovirus vector expressing a dominant-negative IkappaB

131 An adenovirus vector expressing a nonsecreted and nonglycos

132 An adenovirus vector expressing a nonsecreted version of MD

133 ly, the animals could be readministered with adenovirus vector expressing alkaline phosphatase.

134 For embryonic gene transfer, an adenovirus vector expressing beta-galactosidase was inje

135 V2/8 vectors and compared to results with an adenovirus vector expressing Gag (AdC7).

136 ority of ZTA-positive cells, but not with an adenovirus vector expressing green fluorescent protein.

137 ogenicity of a recombinant, non-replicating, adenovirus vector expressing haemagglutinin and double-s

138 Single-dose vaccination with a recombinant adenovirus vector expressing hepacivirus non-structural

139 f HNF-6 either by infection with recombinant adenovirus vector expressing HNF-6 cDNA by growth hormon

140 otential of an [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE, comparing intra

141 We produced an adenovirus vector expressing ID93 (Ad5-ID93) for inducti

142 ss this escape mechanism using a recombinant adenovirus vector expressing interleukin-12 (Ad5IL-12) t

143 eport that the intrapulmonary delivery of an adenovirus vector expressing KARAP/DAP12, an adaptor pro

144 responded to an endotracheally administered adenovirus vector expressing mouse OSM, with marked iBAL

145 t intramuscular administration of E1-deleted adenovirus vector expressing rhesus monkey erythropoieti

146 ciency of dendritic cells transduced with an adenovirus vector expressing secondary lymphoid chemokin

147 dermal fibroblasts by titrating the dose of adenovirus vector expressing TGFbetaRI (AdTGFbetaRI).

148 vented completely by a replication-defective adenovirus vector expressing the anti-inflammatory cytok

149 Intratumoral injection of adenovirus vector expressing the Bar gene suppressed gro

150 d directly from human cells infected with an adenovirus vector expressing the BMRF1 gene product.

151 ing with a replication-defective recombinant adenovirus vector expressing the lymphocytic choriomenin

152 n a replication-defective chimpanzee-derived adenovirus vector expressing the nucleoprotein (NP) of i

153 with a subset receiving the Ad26 vaccine, an adenovirus vector expressing the viral Env/Gag/Pol antig

154 l cycle arrest, we constructed a recombinant adenovirus vector expressing ZTA (Ad-ZTA), whose level o

155 o define factors controlling RCA generation, adenovirus vectors expressing E2F family proteins, known

156 Replication-deficient adenovirus vectors expressing Ebola virus GP induced the

157 nitude of T lymphocyte responses elicited by adenovirus vectors expressing either full-length HIV-1 G

158 acking UL128-131 proteins and nonreplicating adenovirus vectors expressing gH, gL, UL128, UL130, and

159 Adenovirus vectors expressing high levels of VEGF could

160 Adenovirus vectors expressing nef were used to introduce

161 onstrated that immunization with recombinant adenovirus vectors expressing NP and M2 significantly re

162 ells (MCF10A) and fibroblasts (MSU) by using adenovirus vectors expressing p300-specific antisense se

163 ction of CNV was measured in the presence of adenovirus vectors expressing shRNA targeting VEGF.

164 Here we have examined the efficacy of adenovirus vectors expressing the BZLF1 or BRLF1 protein

165 Replication-defective adenovirus vectors expressing the IE72 or IE86 protein w

166 s, we primed mice with replication-defective adenovirus vectors expressing the lymphocytic choriomeni

167 Adenovirus vectors expressing VEGF were subsequently inj

168 Replication-defective adenovirus vectors expressing vIL-10 (AdvIL-10) or LacZ

169 Adenovirus vector expression of M33 was sufficient to pr

170 rate that a replication-deficient chimpanzee adenovirus vector followed by a modified vaccinia virus

171 present an obstacle to the effective use of adenovirus vectors for gene therapy and vaccination.

172 ive to the more commonly used retrovirus and adenovirus vectors for human gene therapy.

173 Rational development of adenovirus vectors for therapeutic gene transfer is hamp

174 re adenovirus infections as well as improved adenovirus vectors for use in vaccination and gene and c

175 ease the therapeutic efficacy of replicating adenovirus vectors for vaccines or oncolytic viral targe

176 ated either with AdHu5 vectors or chimpanzee adenovirus vectors, frequencies of such T cells were exc

177 vectors are more immunogenic than chimpanzee adenovirus vectors from species Human adenovirus E (ChAd

178 ng increased TNF-alpha levels in the lung by adenovirus-vectored gene therapy controlled infection wi

179 We conclude that the stability of the adenovirus vector genome in the livers of intravenously

180 ce of low levels of transcriptionally active adenovirus vector genomes at the site of inoculation, in

181 A control adenovirus vector had minimal antitumor effect in vivo.

182 We describe construction of adenovirus vectors harbouring the bacterial NTR gene und

183 hile pulmonary administration of a high-dose adenovirus vector has been associated with undesirable i

184 Studies with overexpression of GMF using adenovirus vector have uncovered its regulatory role in

185 Adenovirus vectors have a number of advantages for gene

186 tion of plasmid DNA or replication-defective adenovirus vectors have been limited by low transduction

187 Adenovirus vectors have been studied as vehicles for gen

188 for which traditional replication-defective adenovirus vectors have not been effective.

189 therapeutic efficacy, we used high-capacity adenovirus vectors (HC-Ads) as a gene delivery platform.

190 Herein we demonstrate that high-capacity adenovirus vectors (HC-Ads) carrying the conditional cyt

191 ntially growing cells were infected with the adenovirus vector, heat shocked 24 h later, and the radi

192 the procedure and evaluate its efficacy, an adenovirus vector (human adenovirus type 5) encoding a g

193 hat absence of CD4(+) T cells at the time of adenovirus vector immunization of mice led to immediate

194 veness, antibody responses can be induced by adenovirus vector immunization or alum-adjuvanted protei

195 ion injection of the interleukin-12-carrying adenovirus vector in a mouse melanoma tumor model caused

196 mouse brain derived ECs, bEnd3 cells, and an adenovirus vector in order to enhance and control the ex

197 advantage of this property, we generated an adenovirus vector in which E1 gene expression, and there

198 Propagation of E1 region replacement adenovirus vectors in 293 cells results in the rare appe

199 el for the testing of murine armed oncolytic adenovirus vectors in immunocompetent animals.

200 ed action potential alterations, we injected adenovirus vectors in vivo to overexpress or to suppress

201 the effects of virus-specific antibodies on adenovirus vectors in vivo.

202 e a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and efficacy c

203 FX increased transduction by Ad.CMVfLuc, an adenovirus vector, in murine hepatocyte-like cells and h

204 wed that in vivo expression of Flt3L from an adenovirus vector increases the number of CD11b+ and CD1

205 e findings suggest that alternative serotype adenovirus vectors induce potentially important immune r

206 the BZLF1 or BRLF1 vector, but not a control adenovirus vector, induced expression of early lytic EBV

207 Systemic administration of adenovirus and adenovirus vectors induces a robust innate and adaptive

208 ns were originally characterized in HCMV- or adenovirus vector-infected U373 astroglioma cells.

209 ted that addition of 3 microM doxycycline to adenovirus vector-infected Vero cells resulted in a 100-

210 systemic or intratumoral (i.t.) injection of adenovirus vectors into mice increases plasma levels of

211 E proceeds efficiently in cells in which the adenovirus vector is able to replicate.

212 ing the protective efficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of

213 modification of DCs with a recombinant CD40L adenovirus vector may be a useful strategy for directly

214 evel expression of ICP0 from the E1(-) E4(-) adenovirus vector may increase the utility of adenovirus

215 Adenovirus vectors may be designed with tropism to disti

216 ta suggest that inclusion of Ad17 fiber into adenovirus vectors may improve the outlook for gene deli

217 Restoration of TM expression using adenovirus vector-mediated gene transfer significantly e

218 We also demonstrated, by adenovirus vector-mediated RNA interference, that ACTR i

219 In this study we used adenovirus vector-mediated transduction of either the p5

220 The use of an adenovirus vector might confer potential in vivo applica

221 eviously described two replication-competent adenovirus vectors, named KD1 and KD3, for potential use

222 of female mice with a replication-defective adenovirus vector of human serotype 5 (AdHu5) expressing

223 Reversible immobilization of adenovirus vectors on the bare-metal surfaces of endovas

224 es following intramuscular administration of adenovirus vectors on transgene stability has not been e

225 neously with RSV and either an empty control adenovirus vector or one expressing CD40L or were coimmu

226 ere sham infected or infected with a control adenovirus vector or one expressing the super-repressor

227 FN-beta was not directly attributable to the adenovirus vector or virus-mediated cytolysis of tumor c

228 ly low levels of endogenous gB--expressed by adenovirus vectors or after HCMV infection--and stimulat

229 djuvants; (iii) immunized with the UL19/UL47 adenovirus vectors; or (iv) immunized with the combinati

230 s prepared from murine joints, injected with adenovirus vectors overexpressing IL-1 and/or OSM, were

231 ressed in human RPE cells in the presence of adenovirus vectors overexpressing VEGF, and the amount o

232 y retrograde infection from injections of an adenovirus vector, producing enhanced green fluorescent

233 ts demonstrate that intraductal injection of adenovirus vectors provides a versatile and noninvasive

234 Although many recombinant adenovirus vectors (rAd) have been developed, especially

235 ned in COS-1 cells infected with recombinant adenovirus vector (rAdSERCA).

236 ith PIV3, suggesting that treatment with the adenovirus vector, regardless of whether it was carrying

237 e clinical use of adeno-associated virus and adenovirus vectors regulated by rapamycin analogs.

238 Overexpression of PTTG through an adenovirus vector resulted in a significant increase in

239 d truncation mutants of m4/gp34 in a gutless adenovirus vector revealed that the transmembrane region

240 -66 and GFP-66kd) from replication-defective adenovirus vectors revealed that ORF66 reduced MHC-I sur

241 Infection with an adenovirus vector reveals that T cell-mediated immunity

242 Two adenovirus vectors, Shigatoxin1A1 donor (AdStx1A1Do) and

243 ay analysis comparing the effects of HSV and adenovirus vector strains.

244 Expression of the viral Nef protein from an adenovirus vector suggests that Nef contributes to the H

245 Efforts to develop adenovirus vectors suitable for genetic interventions in

246 Here, we found that RIZ1 expression through adenovirus vectors suppressed growth of MSI(+) HCT116 co

247 s may have implications for murine models of adenovirus vector targeting.

248 Inhibiting NF-kappaB with an adenovirus vector that expressed a nondegradable form of

249 We constructed an adenovirus vector that expressed cDNA for both the GABA(

250 on of Vero cells with the test vector and an adenovirus vector that expresses the reverse tetracyclin

251 o-associated virus vectors and by a modified adenovirus vector that had been coupled to the u7-peptid

252 e developed a novel glucocorticoid-inducible adenovirus vector that overproduces MMP1 only in the pre

253 We have used an adenovirus vector that specifically replicates in tumor

254 Novel adenovirus vectors that are currently being developed to

255 In this study, we used replication-deficient adenovirus vectors that contain either a uPAR antisense

256 test this hypothesis, replication-defective adenovirus vectors that express wild-type and mutant for

257 Adenovirus vectors that express wild-type forms of ICP0,

258 We have developed a new class of adenovirus vectors that selectively replicate in tumor c

259 vanced atherosclerosis were treated with the adenovirus vector, there was clear regression of aortic

260 when m4 was carried either by MCMV or by the adenovirus vector, they were only efficiently exported f

261 transfer with a targeted molecular conjugate adenovirus vector through the c-kit receptor in hematopo

262 e latter concept can be incorporated into an adenovirus vector to achieve specific gene inhibition in

263 We used a replication-defective adenovirus vector to deliver the ferritin transgenes.

264 Dendritic cells modified with a recombinant adenovirus vector to express CD40 ligand and pulsed with

265 We used the adenovirus vector to immunize 26 recombinant inbred mous

266 is study, we report the use of a recombinant adenovirus vector to induce regulatory responses for the

267 completely abrogates the ability of a BRLF1 adenovirus vector to induce the lytic form of EBV infect

268 relevance of these correlations, we used an adenovirus vector to maintain Id-2 protein expression in

269 stimulable, adenylyl cyclase type VIII in an adenovirus vector to optimize its expression in the pitu

270 s a rationale for novel strategies to target adenovirus vector to specific tissues and to reduce viru

271 In this study, we used an adenovirus vector to transfer active TGF-beta1 to the gl

272 , therefore, be a powerful agent to retarget adenovirus vectors to epithelial tumor metastases.

273 rotection was also evident in the context of adenovirus vector transduction and HCMV infection of aut

274 ecific immune profiles elicited by different Adenovirus vector types and emphasize the importance of

275 hat over-expression of c-Myc delivered by an adenovirus vector up-regulates endogenous proapoptotic b

276 t formulation conditions, of preparations of adenovirus vectors used in gene therapy and to assess th

277 A simian adenovirus vector vaccine strategy is effective at induc

278 aive macaques were immunized with an SIV-gag adenovirus vector vaccine.

279 n five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing

280 or had been vaccinated using a recombinant, adenovirus-vectored vaccine 2 weeks before challenge.

281 ated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabili

282 l therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85

283 ted the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222),

284 We previously reported that adenovirus vectored vaccines are potent in priming Ab re

285 Ag-specific follicular Th cell responses to adenovirus vectored vaccines exceeded those induced by o

286 We report that adenovirus vectored vaccines induce Ag insert-specific G

287 n future clinical trials of all serotypes of adenovirus-vectored vaccines.

288 An adenovirus vector was constructed and used for CCL18 del

289 seroprevalence of these novel rhesus monkey adenovirus vectors was extremely low in sub-Saharan Afri

290 the expression of ICP0, VP16, and ICP4 from adenovirus vectors was sufficient to reactivate strains

291 e formulations followed by boosting with the adenovirus vector were also compared.

292 of ICP0, ICP4, OBP, and VP16 expressed from adenovirus vectors were functional based on their abilit

293 Replication-defective adenovirus vectors were used to introduce a recombinant

294 f the adenovirus genome in the context of an adenovirus vector with E1 deleted in in vitro and in viv

295 tumor cell lines support DNA replication of adenovirus vectors with deletions of the E1A and E1B gen

296 , we measured rates during the production of adenovirus vectors with genomes containing three differe

297 Testing adenovirus vectors with identical transgene cassettes or

298 chicken and neonatal rat cardiac myocytes by adenovirus vectors, with c-myc tags on both constructs t

299 emory phenotypes; a subsequent boost with an adenovirus vector yielded a brisk expansion of Gag-speci

300 In our previous work, we developed an Adenovirus vectored ZIKV vaccine using a low-seroprevale